Oxatomide in the treatment of atopic dermatitis in breast-fed and very young infants
Boccazzi, A.; Pugni, L.; Cesuti, R.; Rapuzzi, S.
Minerva Pediatrica 53(4): 265-269
2001
ISSN/ISBN: 0026-4946 PMID: 11573062 Document Number: 535923
Background: This study was designed to assess the efficacy and safety of oxatomide oral suspension, in breast-fed and young babies with atopic dermatitis. Methods: Thirty-one children (11 females, 20 males) aged between 4 and 35 months (mean+or-SD 15.4+or-7.6 months) from Italy were treated with oxatomide (2.5 mg/ml) at a dose of (1 mg/kg/day) split into two doses, every 12 h; treatment lasted 30 days . Efficacy was evaluated on the basis of the following signs and symptoms: itching (severity, extension and duration), blisters (number, extension), erythema (severity, extension), papules (number, extension), lesions from scratching (yes/no), dry skin (yes/no). Results: Skin signs improved significantly with oxatomide. Itching was reduced 58.2% from baseline, and erythema 57.6% (both P<0.001). Vesicles, papules, lesions due to scratching and dry skin also improved significantly. Oxatomide had to be stopped only in one child in whom the dermatitis became worse. Conclusions: These results show the efficacy and safety of oxatomide in breast-fed or very young babies with atopic dermatitis. The oral suspension was particularly easy to use in children less than two years old, on account of the simple dosage schedule.